NexImmune, Inc. (NEXI)
Largest Insider Buys in Sector
NEXI Stock Price History Chart
NEXI Stock Performance
About NexImmune, Inc.
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
Insider Activity of NexImmune, Inc.
Over the last 12 months, insiders at NexImmune, Inc. have bought $0 and sold $16,045 worth of NexImmune, Inc. stock.
On average, over the past 5 years, insiders at NexImmune, Inc. have bought $2.43M and sold $16,045 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1 shares for transaction amount of $0 was made by Jones Kristi (President and CEO) on 2024‑06‑11.
List of Insider Buy and Sell Transactions, NexImmune, Inc.
| 2024-06-11 | Jones Kristi | President and CEO | 1 – | $0.01 | $0 | -0.69% | ||
| 2023-11-22 | Sale | Roemer Alan S. | director | 3,992 0.3799% | $1.94 | $7,758 | +87.95% | |
| 2023-11-21 | Sale | Roemer Alan S. | director | 3,833 0.382% | $2.16 | $8,287 | +78.05% | |
| 2023-03-30 | BARER SOL J | director | 400,000 1.6133% | $0.41 | $164,120 | -26.28% | ||
| 2022-11-17 | BARER SOL J | director | 75,000 0.3304% | $0.48 | $35,918 | -28.54% | ||
| 2022-11-16 | BARER SOL J | director | 125,000 0.4914% | $0.48 | $60,300 | -36.47% | ||
| 2022-06-03 | Verstandig Grant | 25,000 0.1084% | $2.14 | $53,538 | -78.24% | |||
| 2022-05-31 | BARER SOL J | 39,280 0.1647% | $2.19 | $85,894 | -79.21% | |||
| 2022-05-31 | Verstandig Grant | 40,200 0.1836% | $2.38 | $95,760 | -79.21% | |||
| 2022-03-29 | Jones Kristi | President and CEO | 10,000 0.0465% | $3.74 | $37,400 | -80.11% | ||
| 2022-03-24 | Verstandig Grant | 131,622 0.6896% | $4.14 | $544,915 | -79.65% | |||
| 2022-03-23 | BARER SOL J | 10,000 0.0442% | $2.67 | $26,653 | -73.33% | |||
| 2022-03-22 | BARER SOL J | 60,000 0.2389% | $2.41 | $144,600 | -73.32% | |||
| 2022-03-21 | BARER SOL J | 60,000 0.2724% | $2.14 | $128,160 | -65.05% | |||
| 2022-03-18 | BARER SOL J | 60,000 0.2551% | $2.11 | $126,420 | -65.94% | |||
| 2021-02-17 | BARER SOL J | director | 120,000 0.6684% | $17.00 | $2.04M | -42.01% | ||
| 2021-02-17 | Verstandig Grant | director | 350,000 1.9494% | $17.00 | $5.95M | -42.01% | ||
| 2021-02-17 | Jones Kristi | Chief Operating Officer | 1,822 0.0101% | $17.00 | $30,974 | -42.01% | ||
| 2021-02-17 | ZELDIS JEROME B | Executive VP of Research & Dev | 11,764 0.0655% | $17.00 | $199,988 | -42.01% |
Institutional Investor Ownership
No records found… | |||||||